[
    [
        {
            "time": "2019-04-04",
            "original_text": "Health Care Sector Update for 04/04/2019: NSPR, REPH, RWLK, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "Sector Update",
                    "PFE"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-10-12",
            "original_text": "The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Highlights",
                    "Pfizer"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-19",
            "original_text": "U.S. FDA Approves IBRANCEÂ® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer",
            "features": {
                "keywords": [
                    "FDA",
                    "Approval",
                    "IBRANCE",
                    "Metastatic Breast Cancer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Vizimpro",
                    "EU Approval",
                    "Lung Cancer"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "U.S., China key to GSK's consumer venture with Pfizer",
            "features": {
                "keywords": [
                    "U.S.",
                    "China",
                    "GSK",
                    "consumer venture",
                    "Pfizer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-15",
            "original_text": "AM Best Affirms Credit Ratings of Blue Whale Re Ltd.",
            "features": {
                "keywords": [
                    "AM Best",
                    "Credit Ratings",
                    "Blue Whale Re Ltd."
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "insurance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 3,
                "Market_Scope": 1,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Pfizer Stock Sinks As Market Gains: What You Should Know",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Stock Sinks",
                    "Market Gains"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer Stock Sinks As Market Gains: What You Should Know",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]